← All trials
NCT05165992
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 28, 2022
- Primary completion
- Nov 30, 2022
- Completion date
- Dec 31, 2022
- First posted
- Dec 21, 2021
- Last posted
- Dec 21, 2021
- Enrollment
- 200
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Hamad Medical CorporationLead sponsor
- Hamad Medical CorporationOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.